Clinical Trial Update: A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase I study of MLN8237 (Aurora A kinase inhibitor) in adults with advanced malignancies; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignancies

Drugs mentioned

• MLN8237 (alisertib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Advanced Malignancies | Phase 1 | Status: COMPLETED | Results posted: 2019-03-15